Total Payments
$46,958
2021 Payments
$152.96
Companies
35
Transactions
363
Medicare Patients
1,848
Medicare Billing
$188,749
Payment Breakdown by Category
Other$30,900 (65.8%)
Consulting$6,700 (14.3%)
Food & Beverage$6,340 (13.5%)
Travel$2,967 (6.3%)
Education$50.22 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,300 | 18 | 47.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,600 | 3 | 18.3% |
| Consulting Fee | $6,700 | 3 | 14.3% |
| Food and Beverage | $6,340 | 323 | 13.5% |
| Travel and Lodging | $2,967 | 13 | 6.3% |
| Education | $50.22 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Synergy Pharmaceuticals Inc | $14,658 | 35 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11,244 | 64 | $0 (2021) |
| Endogastric Solutions, Inc | $8,869 | 11 | $0 (2021) |
| Allergan, Inc. | $8,863 | 49 | $0 (2020) |
| AbbVie Inc. | $605.79 | 48 | $0 (2021) |
| Gilead Sciences, Inc. | $486.12 | 44 | $0 (2020) |
| Covidien LP | $312.46 | 3 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $308.12 | 19 | $0 (2020) |
| Shire North American Group Inc | $177.20 | 5 | $0 (2018) |
| UCB, Inc. | $174.94 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $152.96 | 5 | Endogastric Solutions, Inc ($74.23) |
| 2020 | $711.04 | 51 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($252.04) |
| 2019 | $11,867 | 102 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($10,811) |
| 2018 | $18,938 | 113 | Synergy Pharmaceuticals Inc ($12,099) |
| 2017 | $15,289 | 92 | Allergan Inc. ($7,152) |
All Payment Transactions
363 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/18/2021 | Endogastric Solutions, Inc | ESOPHYX (Device) | Food and Beverage | Cash or cash equivalent | $74.23 | General |
| Category: GERD | ||||||
| 03/08/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Gastroenterology | ||||||
| 01/26/2021 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $32.50 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 01/06/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Gastroenterology | ||||||
| 12/08/2020 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/08/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: IMMUNOLOGY | ||||||
| 11/30/2020 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/30/2020 | EVOKE PHARMA, INC. | GIMOTI (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Gastroenterology | ||||||
| 11/18/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/16/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: IMMUNOLOGY | ||||||
| 11/09/2020 | VIVUS, Inc. | PANCREAZE (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/09/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.53 | General |
| 11/04/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/19/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: IMMUNOLOGY | ||||||
| 10/13/2020 | Janssen Biotech, Inc. | REMICADE (Biological), STELARA, SIMPONI | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Immunology | ||||||
| 10/06/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/28/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.32 | General |
| 09/25/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/14/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $8.11 | General |
| Category: IMMUNOLOGY | ||||||
| 08/31/2020 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $9.52 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/29/2020 | Alfasigma USA, Inc. | — | Food and Beverage | In-kind items and services | $11.98 | General |
| 08/26/2020 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 08/24/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $12.34 | General |
| Category: IMMUNOLOGY | ||||||
| 08/19/2020 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 181 | 182 | $145,102 | $24,508 |
| 2020 | 20 | 1,667 | 1,910 | $678,100 | $164,241 |
Total Patients
1,848
Total Services
2,092
Medicare Billing
$188,749
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 45 | 45 | $66,960 | $8,798 | 13.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 42 | 42 | $15,120 | $6,959 | 46.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 42 | 43 | $11,825 | $2,806 | 23.7% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2023 | 19 | 19 | $28,272 | $2,668 | 9.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 13 | 13 | $8,125 | $2,178 | 26.8% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 20 | 20 | $14,800 | $1,099 | 7.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 250 | 257 | $129,499 | $38,257 | 29.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 302 | 407 | $71,461 | $20,936 | 29.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 59 | 59 | $53,426 | $11,197 | 21.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2020 | 61 | 61 | $33,146 | $10,875 | 32.8% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Facility | 2020 | 79 | 79 | $51,644 | $10,392 | 20.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 125 | 139 | $36,965 | $10,283 | 27.8% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 75 | 75 | $61,065 | $9,119 | 14.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 208 | 289 | $28,007 | $8,444 | 30.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 112 | 141 | $25,303 | $7,446 | 29.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 67 | 68 | $24,262 | $6,909 | 28.5% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 83 | 84 | $43,692 | $6,190 | 14.2% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 78 | 81 | $48,027 | $6,026 | 12.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2020 | 32 | 32 | $23,749 | $5,692 | 24.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 31 | 31 | $13,279 | $3,197 | 24.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $9,856 | $2,661 | 27.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 32 | 32 | $8,184 | $2,227 | 27.2% |
| 43249 | Balloon dilation of esophagus using an endoscope | Facility | 2020 | 13 | 14 | $7,857 | $1,565 | 19.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 16 | $4,468 | $1,275 | 28.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 11 | 11 | $2,262 | $856.22 | 37.9% |
About Dr. Peter Mavrelis, MD
Dr. Peter Mavrelis, MD is a Gastroenterology healthcare provider based in Hobart, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1326043597.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Mavrelis, MD has received a total of $46,958 in payments from pharmaceutical and medical device companies, with $152.96 received in 2021. These payments were reported across 363 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($22,300).
As a Medicare-enrolled provider, Mavrelis has provided services to 1,848 Medicare beneficiaries, totaling 2,092 services with total Medicare billing of $188,749. Data is available for 2 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Hobart, IN
- Active Since 06/15/2005
- Last Updated 12/09/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1326043597
Products in Payments
- Trulance (Drug) $14,658
- TRULANCE (Drug) $10,384
- ESOPHYX (Device) $8,869
- LINZESS (Drug) $7,800
- VIBERZI (Drug) $1,106
- XIFAXAN (Drug) $735.68
- Entyvio (Biological) $295.07
- Humira (Biological) $264.77
- Epclusa (Drug) $247.04
- GATTEX (Drug) $177.20
- Cimzia (Drug) $174.94
- Manometry (Device) $166.44
- Olympus Biliary Devices (Device) $166.17
- XIFAXANIBSD (Drug) $124.43
- STELARA (Biological) $88.62
- Creon (Drug) $88.00
- XELJANZ (Drug) $85.47
- HUMIRA (Biological) $66.23
- DIFICID (Drug) $66.04
- OCALIVA (Drug) $63.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.